Press Releases

The CPHI series of pharma events, the largest exhibitions in pharma, have seen significant growth in Asia in the first half 2023. Double digit attendee growth is expected across most editions – CPHI will host events in China, Japan, India, Korea and Thailand in 2023 – with audiences recovering to pre-pandemic levels and further growth expected in the second half of the year. Informa’s pharma portfolio performance is seen as a good macro indicator for the wider events industr

Astellas Pharma Inc., and Cullgen Inc. today announced a research collaboration and exclusive option agreement to discover multiple innovative protein degraders. Under the terms of the agreement, the two companies aim to develop multiple targeted protein degraders by combining Cullgen's proprietary uSMITE™ targeted protein degradation platform featuring novel E3 ligands with Astellas' drug discovery capabilities. Cullgen and Astellas will collaboratively conduct joint

Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has entered into a research collaboration with AbCellera for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. Confo will apply its proprietary ConfoBody® technology to stabilize the selected GPCRs in their disease-relevant conformations, which will then be used as antigens to enable antibody discovery and development. Con

OKRA.ai, an Envision Pharma Group company, has appointed senior leader Dr. Yahya Anvar as Chief of AI Science & Insights to unleash the full potential of artificial intelligence (AI) and to further support the life sciences industry. "I am excited about continuing the innovative collaboration between Envision and OKRA.ai along with Yahya as a senior leader as it further solidifies our Envision commitment to the expansion of OKRA.ai and leadership in the AI and technical spa

The launch of a new biocompatible hydrogel resin marks the begin of a new era in bioprinting. The novel resin allows 2-photon polymerization 3D-printing from micro- to meso-scale at highest resolution. The reactivity and easy processing of the material permits the fabrication of complex and versatile organ- or lab-on-chip designs. This new bioink called Hydrotech INX© U200 has been developed by the material specialist BIO INX (Belgium) in collaboration with UpNano (Austria), leading manu

Coya Therapeutics, Inc a clinical-stage biotechnology company developing multiple therapeutic programs intended to enhance Treg function, including biologics, today reported additional biomarker and brain imaging results from an open-label proof-of-concept clinical study for COYA 301 in patients with mild to moderate AD. Results of the study will be presented June 7th, 2023, at the LD Micro Conference in Los Angeles, CA. The clinical study data can be viewed here. Highlights

Alentis Therapeutics  the clinical-stage biotechnology company developing treatments for Claudin-1 positive tumors and organ fibrosis, announced today the FDA cleared an IND application for ALE.C04 as a monotherapy and in combination with pembrolizumab, in a first-in-human clinical trial in recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) that is expected to start during the second half of 2023. “With ALE.C04 we aim to treat solid tumors in a unique w

2seventy bio, Inc. a leading immuno-oncology cell therapy company, today announced that the Phase 1 trial of the PLAT-08 study of SC-DARIC33 in Acute Myeloid Leukemia has been paused by Seattle Children’s, the Company’s partner and the regulatory sponsor of the study. The pause was instituted as part of the clinical study protocol stopping rules in response to a recent Grade 5 (fatal) serious adverse event (SAE) and was followed by the required notification to the U.S. Food &

Proventus Bioscience, a biotech company that produces sustainable biological microorganisms for use by various industries, announced the start of construction of its new 20,000-square-foot production plant and corporate headquarters at 4455 Griffith St., Saint-Laurent, QC. Proventus' new 20,000-square foot facility is designed to be compliant with current Good Manufacturing Practices (camps) required by the food industry that include bio-infused products for probiotics, agricult

Indica Labs today announces the launch of a service offering deployment and on-going support of its HALO® digital pathology software in a fully managed cloud-hosted environment powered by Amazon Web Services (AWS). The service enables organizations to benefit from Indica Labs’ software development and cloud deployment expertise while maintaining full ownership and control over their AWS account. Indica Labs’ entire suite of HALO software, including the HALO Image Analysis plat